Investopedia: Will Immunotherapy Disrupt The Oncology Market?

Goldman Sachs' recent list of eight "disruptive technologies" included new therapies to fight cancer, drugs that promise to u...

Investopedia: Better Margins Can't Hide Merck's Growth Challenges

In spite of pretty weak top-line results, pharma companies like Merck (NYSE: MRK ), Pfizer (NYSE: PFE ), and Bristol-Myers (NYSE: BMY ) ...

Seeking Alpha: Celldex Turning Into A Compelling Immunotherapy Biotech

"Shoulda, coulda, woulda" will probably be my investing epitaph. While there is no shortage of investment advice telling you that...

Investopedia: After A Good Run, Novartis Looks Fairly Valued

Like so many other pharmaceutical stocks, Novartis (NYSE: NVS ) has done pretty well for its shareholders over the past year and solidly be...

Investopedia: Roche, Reloaded

There's a saying that you'll hear used with perennially successful sports franchises – they don't rebuild, they reload. That co...

Investopedia: After A Big Rally, Pfizer Might Need Some Rest

Big Pharma has enjoyed an exceptional stretch of performance lately, reversing what had been a relatively rare period of underperformance ...

Investopedia: Amgen Chased By The Bubble

There are two relatively heated debates that bear directly on Amgen (Nasdaq: AMGN ) and its stock. First, is Amgen still really a biotech,...

Seeking Alpha: No News Becoming Bad News For Lexicon Pharmaceuticals

Normally you would think that having a differentiated and proprietary diabetes compound with solid supporting data would make a biotech re...